Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Esteve and AstraZeneca patents disclose therapeutic agents for metabolic disorders

Feb. 19, 2007

FDA accepts for review two sNDAs for Januvia

Feb. 16, 2007

FDA extends review of rimonabant

Feb. 16, 2007

Replagal launching in Japan

Feb. 15, 2007

Hemospan studied in parallel European phase III trials

Feb. 15, 2007

Findings made available from Diabetes Genetics Initiative

Feb. 14, 2007

Ambrx studies next-generation human growth hormone product in phase I/II study

Feb. 14, 2007

Lonafarnib to enter clinic for the treatment of progeria syndromes

Feb. 14, 2007

Recent patents describe new treatments for endocrine-related disorders

Feb. 13, 2007

Ostabolin-C meets primary endpoint in phase II osteoporosis study

Feb. 13, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Circular RNA, the new beast in gene and cell therapy
BioWorld
Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...